Acerta Pharma
As of the edition of 20 October 2026, Acerta Pharma runs 8 drugs, 2 of them marketed; it is on route A at 4 targets and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 2 |
| Active | 1 |
| Went quiet | 1 |
| Stopped | 3 |
| Status not established | 1 |
| Total | 8 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Venetoclax | Ends 2032 (patent) | 1 |
| Acalabrutinib | Ends 2036 (patent) | 1 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 4 targets, route B at 0 targets.
All 4 rows on route A or B
In the product4 company-target rows on route A or B; 1 is not shown here, and no score is.
See all 4 targets where Acerta Pharma needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 27 trials led
- Blood and lymph: 21 trials led
- Immune system: 21 trials led